Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial – Earthtimes

Author : BioMarin Pharmaceutical Inc. NOVATO, Calif. , Feb. 3 /PRNewswire-FirstCall/ — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced results from its Phase 2 multi-center, randomized, double-blind, placebo-controlled clinical study of Read more

Filed under: Health News

Like this post? Subscribe to my RSS feed and get loads more!